Six of Eight Hemoglobin A1c Point-of-Care Instruments Do Not Heed the Non-specific Accepted Analytical Acting Criteria [Point-of-Care Testing] <<>>

Written by Lenters-Westra, E., Slingerland, R. J. on January 1, 1970 – 1:00 am -

Background: Hemoglobin A1c (Hb A1c) point-of-care (POC) instruments are a great extent utilized to take care of rapid-turnaround results in diabetic meticulousness centers. We investigated the conformance of diverse Hb A1c POC instruments (In2it from Bio-Rad, DCA Vantage from Siemens, Afinion and Nycocard from Axis-Shield, Clover from Infopia, InnovaStar from DiaSys, A1CNow from Bayer, and Quo-Test from Quotient Diagnostics) with predominantly accepted playing criteria for Hb A1c.

Methods: The CLSI protocols EP-10, EP-5, and EP-9 were applied to analyse imprecision, accuracy, and proclivity. We assessed colour using 3 certified unessential quotation calculation procedures and the no matter what of the 3 specification methods. Assay conformance with the Citizen Glycohemoglobin Standardization Program (NGSP) certification criteria, as suited from analyses with 2 rare reagent lot numbers for each Hb A1c method, was also evaluated.

Results: Because of unsatisfactory EP-10 results, 2 of the 8 manufacturers incontrovertible not to pursue the valuation. The come to CVs from EP-5 evaluations for the varied instruments with a low and outrageous Hb A1c value were: In2it 4.9% and 3.3%, DCA Vantage 1.8% and 3.7%, Clover 4.0% and 3.5%, InnovaStar 3.2% and 3.9%, Nycocard 4.8% and 5.2%, and Afinion 2.4% and 1.8%. One the Afinion and the DCA Vantage passed the NGSP criteria with 2 strange reagent lot numbers.

Conclusions: Single the Afinion and the DCA Vantage met the acceptance criteria of having a unqualified CV <3% in the clinically applicable cook-stove. The EP-9 results and the calculations of the NGSP certification showed signal differences in analytical playing liaison weird reagent lot numbers for all Hb A1c POC instruments.

<<>>

Tags: ,
Posted in Clinical Chemistry, Point-of-Care Testing |

Comments are closed.

RSS